News | April 02, 2024
Viatris launches RYZUMVl 0.75% in US
The average time of dilation lasts three to eight hours
The average time of dilation lasts three to eight hours
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
US FDA approval based on NEURO-TTRansform Phase III results
Express Scripts to add Zepbound to National Preferred Formulary
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
Subscribe To Our Newsletter & Stay Updated
